NCT00575562View on ClinicalTrials.gov

Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Colorectal Cancer
Interventions
DRUG

KRN330

Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer

Trial Locations (2)

37203

Sarah Cannon Research Institute, Nashville

37232

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.
All Listed Sponsors
lead

Kyowa Kirin, Inc.

INDUSTRY

NCT00575562 - Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer | Biotech Hunter | Biotech Hunter